CN105920166A - Application of gynecological inflammation resistance preparation in preparation of medicine for preventing and treating chronic pelvic pain - Google Patents
Application of gynecological inflammation resistance preparation in preparation of medicine for preventing and treating chronic pelvic pain Download PDFInfo
- Publication number
- CN105920166A CN105920166A CN201610513000.0A CN201610513000A CN105920166A CN 105920166 A CN105920166 A CN 105920166A CN 201610513000 A CN201610513000 A CN 201610513000A CN 105920166 A CN105920166 A CN 105920166A
- Authority
- CN
- China
- Prior art keywords
- preparation
- parts
- chronic pelvic
- pain
- pelvic pain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/533—Leonurus (motherwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/634—Forsythia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
Abstract
The invention belongs to the field of medicines, and relates to application of a gynecological inflammation resistance preparation in preparation of a medicine for preventing and treating chronic pelvic pain. The preparation is prepared from the following raw materials in parts by weight: 200-300 parts of radix sophorae flavescentis, 200-300 parts of polygonum perfoliatum, 100-200 parts of cortex phellodendri, 30-70 parts of fructus forsythiae, 20-40 parts of motherwort, 20-40 parts of phaseolus calcaratus, 20-40 parts of folium artemisiae argyi, 20-40 parts of angelica sinensis and 20-40 parts of radix linderae. By clinical experiments, main symptoms, traditional Chinese medicine syndromes, pelvic masses and hydrops and other indexes of the chronic pelvic pain of a patient are investigated. Experimental data indicate that the gynecological inflammation resistance preparation can be used for remarkably improving main symptoms (lower abdominal swelling pain or prickling) of gynecological inflammation, which is the sequela of pelvic inflammation diseases, with low recurrence rate and stable curative effect, improving traditional Chinese medicine syndromes (downward flow of damp-heat and blood-stasis obstruction), improving living quality and local signs of the patient and preventing recurrence of chronic pelvic pain with excellent safety. Experiment data indicate that the gynecological inflammation resistance preparation has good safety and can be used as an ideal medicine for preventing and treating chronic pelvic pain.
Description
Technical field
The invention belongs to pharmaceutical technology field, be specifically related to anti-woman's inflammation preparation at preparation preventing and treating chronic pelvic pain medicine
In application.
Background technology
Chronic pelvic pain (CPP) refer to aperiodicity, last up to more than 6 months (also have think reach 3 months with
On), invalid to non-opium Drug therapy pelvic pain.Chronic pelvic pain be the modal symptom of women it
One.The organic diseases such as chronic pelvic inflammatory disease, endometriosis, adenomyosis, pelvic adhesion can cause
Pain, but also have many patients to only have slight pathological change or without organic change.
Pelvic inflammatory disease (pelvic inflammatory disease, PID) is the modal diseases of the women of child-bearing age
One of sick, inflammation often involves uterus, fallopian tube, ovary and surrounding connective tissue etc., and can involve abdominopelvic cavity peritoneum.
How to fall ill owing to sexually transmitted disease (STD) infection, puerperal, post-abortion and gynecologic surgery antibacterial enter traumatic infection,
Morbidity can be confined to a position, several position or whole pelvic cavity.As pelvic inflammatory disease does not obtains timely
Correct treatment, then can occur its clinical manifestation of a series of sequela, i.e. sequelae of pelvic inflammatory disease to include
Infertile, ectopic pregnancy, chronic pelvic pain and pelvic inflammatory disease recurrent exerbation.There are about gynecological's door of 1/10th
Examine patient to seek medical advice with chronic pelvic pain for cardinal symptom.After chronic pelvic pain (CPP) is as pelvic inflammatory disease
Lose one of disease, mostly be pelvic inflammatory disease and fail thoroughly to treat, or the delay of patient's body constitution poor course of disease is caused, the state of an illness
More obstinate, patient's Chang Yin pain obstinate and the most painful.Show as under prolonged and repeated outbreak clinically more
Abdominal part falling inflation pain, lumbosacral region are ached sense, tired or sexual intercourse postemphasis, or with fatigue and weak, low grade fever, Yi Jijing
God's neurasthenia symptom such as depressed, insomnia, more difficult cures completely, severely compromises the physical and mental health of numerous women,
The sickness rate of primary disease is in the trend gradually risen in recent years.
Doctor trained in Western medicine is many based on antiinflammatory for the chronic pelvic pain caused by treatment pelvic inflammatory disease, single from anti-inflammatory treatment
On see, the effect of pain relieving is the most inconspicuous, and treatment pain aspect sometimes needs to add with analgesics, but is not particularly suited for long
The pain therapy of phase, Chinese medicine has big advantage in this aspect treatment comparatively speaking.Listed is anti-
Woman's inflammation capsule be with 9 kinds of medical materials such as Radix Sophorae Flavescentis, Herba Polygoni cymosi, Cortex Phellodendri, Fructus Forsythiae, Herba Leonuri for raw material make pure in
Medicine preparation, has effect of blood circulation promoting and blood stasis dispelling, heat clearing and damp drying, be mainly used in damp heat downward flowing type pelvic inflammatory disease, vaginitis,
Chronic cervicitis, disease sees the diseases such as leucorrhea with red and white discharge, pudendal pruritus, hemorrhage, dysmenorrhea.As it has been described above, anti-woman's inflammation preparation pair
The action effect such as pelvic inflammatory disease, vaginitis is good, but relevant anti-woman's inflammation preparation is in treatment sequelae of pelvic inflammatory disease
The effect of-chronic pelvic pain (CPP) has no report, and therefore Effect of Anti woman inflammation preparation is in treatment chronic pelvic pain institute
The inferior belly gas pain of performance or the cardinal symptom such as twinge, the situation such as TCM syndrome, pelvic lump and hydrops, and in advance
The recurrences of anti-CPP etc. are significant.
Summary of the invention
It is an object of the invention to provide the application in preparation treatment chronic pelvic pain medicine of the anti-woman's inflammation preparation.
It is a further object of the present invention to provide anti-woman's inflammation preparation answering in the medicine that preventing chronic pelvic pain recurs
With.
Described chronic pelvic pain is the sequela caused by pelvic inflammatory disease；Western medicine diagnose shows as hypogastric region and holds
Continuous property dull pain, falling inflation companion's lumbosacral region is ached；Menstrual period, suffer from cold and tired postemphasis, can have vaginal secretions simultaneously
Increase, menorrhagia or vagina dripping hemorrhage.Standards of Chinese Medical Syndrome Differentiation is damp invasion of lower energizer, syndrome of static blood blocking collaterals.
Anti-woman's inflammation preparation of the present invention be by Radix Sophorae Flavescentis, Herba Polygoni cymosi, Cortex Phellodendri, Fructus Forsythiae, Herba Leonuri, Semen Phaseoli,
The preparation of the various dosage forms that Folium Artemisiae Argyi, Radix Angelicae Sinensis, Radix Linderae nine traditional Chinese medicines are prepared from as raw material.
Anti-woman's inflammation preparation of the present invention, calculates in parts by weight, following raw material medicaments is prepared from: Radix Sophorae Flavescentis
200-300 part, Herba Polygoni cymosi 200-300 part, Cortex Phellodendri 100-200 part, Fructus Forsythiae 30-70 part, Herba Leonuri 20-40
Part, Semen Phaseoli 20-40 part, Folium Artemisiae Argyi 20-40 part, Radix Angelicae Sinensis 20-40 part, Radix Linderae 20-40 part.
Say accurately, calculate in parts by weight, following raw material medicaments be prepared from: Radix Sophorae Flavescentis 250 parts, Herba Polygoni cymosi
250 parts, Cortex Phellodendri 150 parts, Fructus Forsythiae 50 parts, Herba Leonuri 30 parts, Semen Phaseoli 30 parts, Folium Artemisiae Argyi 30 parts, when
Return 30 parts, the Radix Linderae 30 parts.
Preparation method of the present invention is that by certain technique, crude drug is prepared as pharmaceutical preparation, its preparation method
Belong to prior art, can obtain from file disclosed in existing patent, or according to technical literature disclosed in other
And prepared by drug standard.
Anti-woman's inflammation preparation of the present invention can be any pharmaceutically useful dosage form, and these dosage forms include: coated tablet,
The tablets such as enteric coatel tablets, buccal tablet, Film coated tablets, hard capsule, soft capsule, oral liquid, granule, punching
Agent, honey pill agent, drop pill, powder, unguentum, sublimed preparation, suspensoid, powder, solution, injection, bolt
Agent, spray, patch.
Anti-woman's inflammation preparation of the present invention, its preparation can be containing conventional excipient, such as binding agent, filling
Agent, tablet agent, diluent, wetting agent, disintegrating agent, coloring agent, flavoring agent, wetting agent and pharmaceutical carrier material
Material.
Anti-woman's preferred KANGFUYAN JIAONANG of inflammation preparation of the present invention.
Anti-woman's inflammation preparation of the present invention determines usage and dosage according to the situation of patient in use.The most list
The KANGFUYAN JIAONANG produced by Yuanchen Pharmaceutical Co., Ltd., Guizhou Prov., every dress 0.35g, usage and dosage is mouth
Clothes, three times a day, each 4.
Chronic pelvic pain (CPP) is as one of sequelae of pelvic inflammatory disease, and current clinical research has following several
Point is for mainly to study a little: 1, doctor trained in Western medicine cardinal symptom inferior belly gas pain or twinge, and uterine activity is limited or adhesion
Fixing with tenderness, attachment area (strand increases thick or lamellar thickens or enclosed mass) tenderness；2, Standards of Chinese Medical Syndrome Differentiation
For damp invasion of lower energizer, syndrome of static blood blocking collaterals.
For probing into the application at treatment chronic pelvic pain of the anti-woman's inflammation preparation, during the present invention selects 240 example clinics to meet
The patient of the chronic pelvic pain of doctor trained in Western medicine disease diagnostic criteria, is randomly divided into matched group and anti-woman's inflammation treatment group；Treatment
After end cycle, observe gynaecologic vaginal color ultrasound, serum CA-125, erythrocyte sedimentation rate, vaginal secretions plate coating checking etc.
The diagnostic test of aspect, and health giving quality evaluation index (cardinal symptom improvement degree, curative effect of disease, the traditional Chinese medical science
Syndrome, individual event symptom and sign, pelvic lump and hydrops, quality of life, recurrent pain), safety indexes.
Result shows: anti-woman's inflammation group treatment sequelae of pelvic inflammatory disease-chronic pelvic pain can be obviously improved patient's lower abdomen
Distending pain or twinge, and relapse rate is low, stable curative effect；Higher curative effect of disease can be obtained, cure-remarkable-effectiveness rate apparently higher than
Matched group.Improve tcm syndrome and the limited tenderness of uterine activity, ride side attachment thickens enclosed mass, right adnexa tenderness,
Left side attachment thickens enclosed mass.Relative to matched group, anti-woman's inflammation preparation can also improve patients ' life quality value of utility and
Quality-adjusted life year.Indicate anti-woman's inflammation preparation to treatment chronic pelvic pain, preventing chronic pelvic pain recurrence tool
There are significant curative effect, clinic popularization and application.
Detailed description of the invention:
For a better understanding of the present invention, use following experimental example, its new application in pharmaceutical field is described.Under
State experiment to be intended to illustrate rather than limitation of the present invention.
Experimental example:
1, to derive from Beijing Chinese medicine between in JIUYUE, 2014 in November ,-2015 big for clinical data all cases
Learn 10 clinical trials unit patients such as east hospital, Chongqing Hospital of Traditional Chinese Medicine, through sequelae of pelvic inflammatory disease-
Chronic pelvic pain Western medicine diagnose standard and traditional Chinese medical science damp invasion of lower energizer, syndrome of static blood blocking collaterals CM syndrome differentiation criterion combine, and meet basin
Chamber inflammatory diseases sequela diagnostic criteria, lasting more than 6 months patients of chronic pelvic pain, totally 240 example, at random
It is divided into treatment group (anti-woman is scorching), each 120 examples of matched group (GONGYANPING)；Each group be meet Chinese medical discrimination belong to
Damp invasion of lower energizer, syndrome of static blood blocking collaterals diagnostic criteria person, the women in age 20-50 year, menstrual cycle is 28～35
My god, married or sexual intercourse history person, chronic pelvic pain pain degree (VAS) scoring >=4.Each group before entering group
Disease is merged in 2 weeks before age, vital sign, case source, the course of disease, previously treatment history, allergies, treatment
And the aspect such as medication is through statistical test no significant difference.
2, Therapeutic Method: treatment group: KANGFUYAN JIAONANG, oral, one time 4,3 times on the one, the course for the treatment of is
12 weeks；Treatment group: medical capsule for treating pelvic inflammatory disease, oral, one time 4,3 times on the one.
3, the course for the treatment of with follow up a case by regular visits to:
The course for the treatment of: 12 weeks (drug withdrawal in menstrual period).
Follow up a case by regular visits to: maximum duration is that 1 menstrual cycle (obtains effector with cardinal symptom " inferior belly gas pain or twinge "
(being evaluated as " excellent "), as following up a case by regular visits to object, follows up a case by regular visits to the recurrence time point that terminal is cardinal symptom；If after treatment terminates
1 menstrual cycle recidivist not yet, then with it for following up a case by regular visits to terminal).
4, time point is observed
Make a house call for (1) the 1st time (-7～0 days, clean period the 3rd～5 day)；
Make a house call for (2) the 2nd times (treating the 28th ± 2 day)；
Make a house call for (3) the 3rd times (treating the 56th ± 2 day)；
(4) the 4th makes a house call (treating the 84th ± 4 day, i.e. the 3rd menstrual cycle terminates)；
(5) follow-up period (treatment is the longest 1 menstrual cycle after terminating).
5, drug combination standard
(1) test carries out period, and pelvic inflammatory disease person occurs in experimenter, presses out group and processes；Can be according to disease
Feelings need to give infection, suit the medicine to the illness, the corresponding treatment such as support；
(2) other treatment sequelae of pelvic inflammatory disease-chronic pelvic pain Chinese medicine and western medicine system is prohibitted the use of during test
Other therapies such as agent and physical therapy；
(3) suffers from the experimenter of underlying diseases, all medicines must will taken during this test is carried out
Giving doctor to check, doctor must record medicine name (or other therapy names), consumption, use time in research case history
Number and time etc., in order to analyzed during summary and report.
6, clinical evaluation index
6.1 diagnostic tests:
(1) gynaecologic vaginal color ultrasound；
(2) erythrocyte sedimentation rate, vaginal secretions plate coating checking；
(3) serum CA-125.
6.2 health giving quality evaluation indexes
6.2.1 curative effect index
(1) cardinal symptom (inferior belly gas pain or twinge) improves degree (pain degree VAS scoring)；Medication
Before, treatment after the 28th ± 2 day, treatment after the 56th ± 2 day, treatment after the 84th ± 4 day (i.e. the 3rd menstruation week
Phase terminates), each observational record of follow-up period 1 time.
(2) curative effect of disease (cardinal symptom+locally sign): before medication, after treatment the 28th ± 2 day, after treatment
56th ± 2 day, treatment after (i.e. the 3rd menstrual cycle terminates), each observational record of follow-up period 1 in the 84th ± 4 day
Secondary.
6.2.2 secondary efficacy index
(1) tcm syndrome；
(2) each individual event symptom and sign；
(3) pelvic lump and hydrops；
(4) quality of life scale evaluation (EQ-5D)；
(5) 1 menstrual cycle hypogastralgia recurrence is followed up a case by regular visits to.
6.3 safety primary evaluation indexs
(1) vital sign: body temperature, breathing, pulse, blood pressure etc.；
(2) routine blood test, routine urinalysis, just conventional (1/3 case is done at each center), liver function (AST, ALT,
TBIL, γ-GT, ALP), renal function (BUN, Cr) and Electrocardioscopy；
(3) adverse events is observed and record.
7, experimental result
The reasons such as after experiment terminates, removing patient comes off, rejecting, effective case load i.e. meets scheme collection (PPS)
Totally 207 examples (treatment group 102 example, matched group 105 example), accounts for 86.25% into group case.
7.1 curative effect
7.1.1 primary symptom (inferior belly gas pain or twinge) VAS scoring difference improves situation, and result see table 1:
Table 1: primary symptom (inferior belly gas pain or twinge) VAS scoring difference improves situation
Note: terminate compared with rear result with treatment before representing patient treatment after baseline-treatment；Baseline-3 expressions of making a house call
Compared with (treating the 56th ± 2 day) result of making a house call with the 3rd time before Zhi Liao
Upper table shows: comparitive study between treatment group and matched group after treatment, checks through t, P < 0.05, shows to control
Treatment group is improved VAS scoring curative effect and is better than matched group, and in 3 differences i.e. embodying both of making a house call.
7.1.2 curative effect of disease evaluation (traditional Chinese medical science primary symptom+locally sign), result see table 2:
Table 2: curative effect of disease is evaluated
Disease cure-remarkable-effectiveness rate (cure rate+obvious effective rate) analysis result shows: treat between treatment group and matched group after treatment
Effect compares, and through X 2 test, P < 0.05, difference has significant, shows treatment group disease cure-remarkable-effectiveness rate curative effect
It is better than matched group, and in 3 differences i.e. embodying both of making a house call.
7.2 secondary treatment indexs
7.2.1 tcm syndrome efficacy evaluation
Chinese medicine syndrome integral cure-remarkable-effectiveness rate (cure rate+obvious effective rate) analysis result shows, after treatment terminates, and treatment
Group more shows 62 examples, and cure-remarkable-effectiveness rate is 60.78%, and matched group more shows 48 examples, and cure-remarkable-effectiveness rate is 45.71%, through card side
Inspection, between treatment group and matched group group, comparing difference statistically significant (P ＜ 0.05), shows the treatment group traditional Chinese medical science
The cure-remarkable-effectiveness rate of therapeutic effect of syndrome is higher than matched group.
7.2.2 individual event symptom efficacy evaluation
Inferior belly gas pain cure-remarkable-effectiveness rate analysis result shows, after treatment terminates (after the 3rd menstrual cycle terminates), controls
Treatment group more shows 45 examples, and cure-remarkable-effectiveness rate is 44.12%, and matched group more shows 27 examples, and cure-remarkable-effectiveness rate is 25.71%, through card
Side's inspection, between treatment group and matched group group, comparing difference statistically significant (P ＜ 0.05), shows that treatment group is excellent
In matched group；And make a house call 3 time, treatment group more shows 16 examples, and cure-remarkable-effectiveness rate is 15.69%, and matched group is the most aobvious
5 examples, cure-remarkable-effectiveness rate is 4.76%, and through between X 2 test, treatment group and matched group group, comparing difference has statistics to anticipate
Justice (P ＜ 0.05), show the treatment group cure-remarkable-effectiveness rate at treatment individual event symptom inferior belly gas pain higher than matched group, and
Make a house call 3 differences i.e. embodying both.
Abdominal pain in menstruation increases the weight of analysis result and shows, the 2nd time make a house call (treating the 28th ± 2 day), treatment group is the most aobvious
13 examples, cure-remarkable-effectiveness rate is 12.75%, and matched group more shows 4 examples, and cure-remarkable-effectiveness rate is 3.81%, through X 2 test, controls
Comparing difference statistically significant (P ＜ 0.05) between treatment group and matched group group.Show that treatment group effect is better than comparison
Group.
Big loose stool and not well effective percentage analysis result show, make a house call for the 2nd time (treating the 28th ± 2 day), treat
Organizing effective 25 examples, effective percentage is 21.19%, and effective 12 examples of matched group, effective percentage is 10.17%, through card side
Inspection, comparing difference statistically significant (P ＜ 0.05) between treatment group and matched group group.Show treatment group effect
It is better than matched group.
Other individual event symptoms (profuse leukorrhea, waist sacrum distending pain, menostaxis, bitter taste greasy taste in the mouth, uncomfortable in chest, poor appetite,
Urine yellow skin, it is hard and dry) respectively make a house call an effective percentage and cure-remarkable-effectiveness rate analysis result shows, medication group all can be one
Determine in degree, to alleviate pelvic inflammatory associated disease symptom, and two groups of results are close, through X 2 test, between two groups of groups
The equal not statistically significant of comparing difference (P > 0.05).
7.2.3 individual event sign efficacy evaluation
The limited tenderness of uterine activity, right adnexa thicken enclosed mass, right adnexa tenderness from the results of view, after treatment terminates
There is significant difference (P < 0.05) between cure-remarkable-effectiveness rate group, and uterine activity adnexa limited, right thickens enclosed mass cure-remarkable-effectiveness rate
In make a house call 3 time group between had significant difference (P < 0.05), right adnexa tenderness cure-remarkable-effectiveness rate is in making a house call 3 and control
After treatment terminates, between group, more all there is significant difference (P < 0.05), show that treatment group is subject to improving uterine activity
Pressure limiting pain, right adnexa thicken and are better than matched group in enclosed mass, three individual event sign curative effects of right adnexa tenderness.Additionally left
Side adnexa thickens enclosed mass and terminates more also have significant difference (P < 0.05) between cure-remarkable-effectiveness rate group in treatment.
The therapeutic evaluation of 7.3 quality of lifes
Statistical result shows, treatment group is improved and quality-adjusted life year with matched group patients ' life quality value of utility
Respectively statistically significant (P < 0.05), treatment group is better than matched group to difference.
7.4 chronic pelvic pain recurrences
During two groups of patients follow up a case by regular visits to a menstrual cycle after treatment is finished, treatment group and matched group chronic pelvic pain
Relapse rate is respectively 1 example (2.56%), 5 examples (21.74%), comparing difference statistically significant (P < 0.05) between group,
Show that treatment group relapse rate is less than matched group.
Above-mentioned experimental example shows: anti-woman's inflammation preparation for treating sequelae of pelvic inflammatory disease-chronic pelvic pain can be substantially
Improve patient's inferior belly gas pain or twinge, and relapse rate is low, stable curative effect；Higher curative effect of disease can be obtained, more
Aobvious rate is apparently higher than matched group；Tcm syndrome can be improved, the limited tenderness of uterine activity, ride side attachment thicken enclosed mass,
Right adnexa tenderness, left side attachment thicken enclosed mass.Relative to control drug, it is raw that anti-woman's inflammation preparation can also improve patient
Effectiveness of quality value of living and quality-adjusted life year.Additionally, medication group adverse reaction rate and type all similar,
Incidence rate is low, and the state of an illness is light, and safety is good, shows that anti-woman's inflammation preparation is for treating sequelae of pelvic inflammatory disease
-chronic pelvic pain is evident in efficacy, and safety is good, clinic popularization and application.
Claims (8)
- The application in the medicine of preparation treatment chronic pelvic pain of the most anti-woman's inflammation preparation.
- The application in the medicine preparing the recurrence of preventing chronic pelvic pain of the most anti-woman's inflammation preparation.
- Apply the most as claimed in claim 1, it is characterised in that described chronic pelvic pain is caused by pelvic inflammatory disease Sequela.
- 4. such as the application of claim 1 or 2, it is characterised in that described chronic pelvic pain Western medicine diagnose shows as down Abdominal part persistence dull pain, falling inflation companion's lumbosacral region is ached；Menstrual period, suffer from cold and tired postemphasis, can have vagina simultaneously Secretions increase, menorrhagia or vagina are dripping hemorrhage.
- 5. such as the application of claim 1 or 2, it is characterised in that described chronic pelvic pain Standards of Chinese Medical Syndrome Differentiation is wet Heat bet, syndrome of static blood blocking collaterals.
- 6. the application as described in claim 1-4 is arbitrary, it is characterised in that described anti-woman's inflammation preparation, according to weight Part calculates, following raw material medicaments be prepared from: Radix Sophorae Flavescentis 200-300 part, Herba Polygoni cymosi 200-300 part, Cortex Phellodendri 100-200 part, Fructus Forsythiae 30-70 part, Herba Leonuri 20-40 part, Semen Phaseoli 20-40 part, Folium Artemisiae Argyi 20-40 part, Radix Angelicae Sinensis 20-40 part, Radix Linderae 20-40 part.
- Applying the most as claimed in claim 6, described anti-woman's inflammation preparation is KANGFUYAN JIAONANG.
- Applying the most as claimed in claim 7, described KANGFUYAN JIAONANG, its preparation method belongs to prior art, permissible Obtain from existing patent or non-patent publication, or prepare according to the disclosed national drug standards.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610513000.0A CN105920166A (en) | 2016-07-01 | 2016-07-01 | Application of gynecological inflammation resistance preparation in preparation of medicine for preventing and treating chronic pelvic pain |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610513000.0A CN105920166A (en) | 2016-07-01 | 2016-07-01 | Application of gynecological inflammation resistance preparation in preparation of medicine for preventing and treating chronic pelvic pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105920166A true CN105920166A (en) | 2016-09-07 |
Family
ID=56828808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610513000.0A Pending CN105920166A (en) | 2016-07-01 | 2016-07-01 | Application of gynecological inflammation resistance preparation in preparation of medicine for preventing and treating chronic pelvic pain |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105920166A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107375498A (en) * | 2017-08-22 | 2017-11-24 | 贵州远程制药有限责任公司 | Anti- woman's inflammation preparation is preparing the application in treating Asherman's syndrom medicine |
| CN115120653A (en) * | 2022-07-19 | 2022-09-30 | 新疆维吾尔医学专科学校第一附属医院 | Application for treating pelvic inflammatory disease and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1418660A (en) * | 2002-11-03 | 2003-05-21 | 贵州远程制药有限责任公司 | Capsule for treating gynaecological inflammation |
-
2016
- 2016-07-01 CN CN201610513000.0A patent/CN105920166A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1418660A (en) * | 2002-11-03 | 2003-05-21 | 贵州远程制药有限责任公司 | Capsule for treating gynaecological inflammation |
Non-Patent Citations (1)
| Title |
|---|
| 程湘等: "妇科疾病患者情绪障碍伴发情况的调查与治疗分析", 《重庆医学》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107375498A (en) * | 2017-08-22 | 2017-11-24 | 贵州远程制药有限责任公司 | Anti- woman's inflammation preparation is preparing the application in treating Asherman's syndrom medicine |
| CN107375498B (en) * | 2017-08-22 | 2020-12-15 | 贵州远程制药有限责任公司 | Application of gynecological inflammation resisting preparation in preparation of medicine for treating intrauterine adhesion |
| CN115120653A (en) * | 2022-07-19 | 2022-09-30 | 新疆维吾尔医学专科学校第一附属医院 | Application for treating pelvic inflammatory disease and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102370725A (en) | Traditional Chinese medicine compound preparation for treating chronic pelvic inflammation and preparation method thereof | |
| Zhao et al. | Chinese medicine sequential therapy improves pregnancy outcomes after surgery for endometriosis-associated infertility: a multicenter randomized double-blind placebo parallel controlled clinical trial | |
| CN103349766B (en) | Pharmaceutical composition for endless postpartum lochia | |
| CN103565954A (en) | Application of Wantong muscle and bone patch in medicament for treating scapulohumeral periarthritis | |
| CN105920166A (en) | Application of gynecological inflammation resistance preparation in preparation of medicine for preventing and treating chronic pelvic pain | |
| CN103705648B (en) | A kind of Chinese medicine composition treating puerperal infection | |
| CN105250519B (en) | It is a kind of alleviate sequelae of pelvic inflammatory disease Chinese medicine composition and its application | |
| CN101199815B (en) | Medicament compound for treating rheumatism, rheumatoid arthritis | |
| CN113750205A (en) | Traditional Chinese medicine composition for relieving and/or treating female reproductive system diseases | |
| CN103948883A (en) | Traditional Chinese medicine composition for treating infertility caused by cold uterus | |
| CN113521175A (en) | New use of a Chinese medicinal composition in preparing medicine for treating male teratospermia | |
| CN101019981A (en) | Chinese medicine prepn and its preparing process | |
| CN111905002B (en) | Traditional Chinese medicine preparation for treating sequelae of pelvic inflammatory disease and preparation method and application thereof | |
| CN101181599B (en) | Chinese medicine composition for curing chronic pelvic inflammatory disease as well as application thereof | |
| CN103372063B (en) | Traditional Chinese medicine composition for treating sequelae of pelvic inflammatory disease and use thereof | |
| CN105560668A (en) | Pharmaceutical composition for curing immune infertility | |
| CN103536706B (en) | A kind of Chinese medicine for the treatment of trimester of pregnancy monilial vaginitis smokes lotion | |
| CN112545977B (en) | Medicinal composition for treating pelvic inflammation and preparation method thereof | |
| CN101601832A (en) | A kind of medicine for the treatment of chronic pelvic inflammatory disease and preparation method thereof | |
| CN1137719C (en) | Chinese medicine for treating chronic salpingitis | |
| CN111759970A (en) | Traditional Chinese medicine composition, preparation method thereof and application thereof in preparation of medicines or health-care products for treating chronic pelvic inflammation | |
| CN101181471B (en) | Medicament for curing pelvic inflammatory disease and preparation method thereof | |
| CN104873866A (en) | Dandelion and rhizoma smilacis glabrae medical preparation for treating pelvic inflammation and detection method thereof | |
| CN116637160A (en) | Spleen-invigorating kidney-tonifying dampness-eliminating pill and application thereof in treating spleen deficiency and damp-excess syndrome of sequelae of pelvic inflammatory disease | |
| CN104644996A (en) | Medicine composition for treating hyperplasia of mammary glands and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160907 |